Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Prepublished online as a Blood First Edition Paper on May 1, 2003; DOI 10.1182/blood-2002-11-3407.

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2002-11-3407v1
102/4/1241    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sauce, D.
Right arrow Articles by Robinet, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sauce, D.
Right arrow Articles by Robinet, E.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted November 8, 2002
Accepted April 14, 2003

Retrovirus-mediated gene transfer in polyclonal T cells results in lower apoptosis and enhanced ex vivo cell expansion of CMV-reactive CD8 T cells as compared to EBV-reactive CD8 T cells

Delphine Sauce, Nathalie Rufer, Patricia Mercier, Marie Bodinier, Jean-Paul Remy-Martin, Anne Duperrier, Christophe Ferrand, Patrick Herve, Pedro Romero, Francois Lang, Pierre Tiberghien, and Eric Robinet*

INSERM E-0119, UPRES EA-2284, EFS Bourgogne Franche-Comte, Besancon, France
NCCR Molecular Oncology, Swiss Institute for Cancer Research, Epalinges, Switzerland
INSERM, Unite 463, Institut de Biologie, Nantes, France
Multidisciplinary Oncology Center, University Hospital, Lausanne, Switzerland

* Corresponding author; email: eric.robinet{at}efs.sante.fr.

To modulate alloreactivity after hematopoietic stem cell transplantation, "suicide" gene-modified donor T cells (GMC) have been administered with an allogeneic T-cell-depleted marrow graft. We previously demonstrated that such GMC, generated after CD3 activation, retrovirus-mediated transduction and G418-selection, had an impaired Epstein-Barr Virus (EBV) reactivity, likely to result in an altered control of EBV-induced lymphoproliferative disease. To further characterize the anti-viral potential of GMC, we compared the frequencies of cytomegalovirus (CMV)- specific CD8+ T (CMV-T) cells and EBV-specific CD8+ T cells (EBV-T) within GMC from CMV- and EBV-double seropositive donors. Unlike anti-EBV responses, the anti-CMV responses were not altered by GMC preparation. During the first days of culture, CMV-T cells exhibited a lower level of CD3-induced apoptosis than did EBV-T cells. In addition, the CMV-T cells escaping initial apoptosis subsequently underwent a higher expansion rate than EBV-T cells. The differential early sensitivity to apoptosis could be in relation with the "recent activation" phenotype of EBV-T cells as evidenced by a higher level of CD69 expression. Furthermore, EBV-T cells were found to have a CD45RA- CD27+ CCR7- effector memory phenotype while CMV-T cells had a CD45RA+ CD27- CCR7- terminal effector phenotype. Such differences could be contributive, since bulk CD8+ CD27- cells had a higher expansion than did bulk CD8+ CD27+ cells. Overall, ex vivo T-cell culture differentially affects apoptosis, long-term proliferation and overall survival of CMV-T and EBV-T cells. Such functional differences need to be taken into account when designing cell and/or gene therapy protocols involving ex vivo T-cell manipulation.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
M. Deschamps, P. Mercier-Lethondal, J. M. Certoux, C. Henry, B. Lioure, C. Pagneux, J. Y. Cahn, E. Deconinck, E. Robinet, P. Tiberghien, et al.
Deletions within the HSV-tk transgene in long-lasting circulating gene-modified T cells infused with a hematopoietic graft
Blood, December 1, 2007; 110(12): 3842 - 3852.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
F. Ciceri, C. Bonini, S. Marktel, E. Zappone, P. Servida, M. Bernardi, A. Pescarollo, A. Bondanza, J. Peccatori, S. Rossini, et al.
Antitumor effects of HSV-TK engineered donor lymphocytes after allogeneic stem-cell transplantation
Blood, June 1, 2007; 109(11): 4698 - 4707.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
N. Schaft, B. Lankiewicz, J. Drexhage, C. Berrevoets, D. J. Moss, V. Levitsky, M. Bonneville, S. P. Lee, A. J. McMichael, J.-W. Gratama, et al.
T cell re-targeting to EBV antigens following TCR gene transfer: CD28-containing receptors mediate enhanced antigen-specific IFN{gamma} production
Int. Immunol., April 1, 2006; 18(4): 591 - 601.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020